Abstract:

Introduction: half-year data on results of using new domestic NanoMed devices for closing atrial septal defects (ASD) were obtained. The occluder is a nitinol self-expanding and self-centering double disc device with a polyester membrane.

Aim: was to evaluate the safety and efficacy of a new domestic occluder for closing of atrial septal defect in a small group of patients over a 6-month follow-up period.

Material and methods: four pediatric patients underwent closure of atrial septal defects with domestic NanoMed occluders. Clinical examination and transthoracic echocardiography were performed at 24 hours, 1, 3, and 6 months. Endpoints included technical success of intervention, efficacy and safety of the procedure at follow-up instrumentation and physical examination.

Results: the average age of patients was 5,2 years (range 4 to 7 years). Mean ASD diameters and device waist sizes were 11,9 ± 1,2 mm and 13,7 ± 1,2 mm and 13,7 ± 1,2 mm, respectively. Technical and procedural success achieved in 100% of cases. During the six-month follow-up, no adverse events and residual flows were identified.

Conclusion: initial half-year data on the absence of adverse events and residual flows indicate the safety and effectiveness of the use of NanoMed occluders.

References

1.     Stout K, Daniels C, Aboulhosn J, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73(12): 1494-1563.

https://doi.org/10.1016/j.jacc.2018.08.1028

2.     Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. Journal of the American Society of Echocardiography. 2008; 21(8): 922-934.

https://doi.org/10.1016/j.echo.2008.02.006

3.     Gillespie MJ, Javois AJ, Moore P, et al. Use of the GORE CARDIOFORM septal occluder for percutaneous closure of secundum atrial septal defects: results of the multicenter U.S. IDE trial. Catheterization and Cardiovascular Interventions. 2020; 95(7): 1296-1304.

https://doi.org/10.1002/ccd.28814

4.     Sharifi M, Burks J. Efficacy of clopidogrel in the treatment of post-ASD closure migraines. Catheter Cardiovasc Interv. 2004; 63: 255.

https://doi.org/10.1002/ccd.20144

Abstract:

Chemodectomas are rare, in most cases, benign neoplasms. They originate from the chemoreceptor cells of the carotid glomus in the bifurcation of the carotid artery. Chemodectoma treatment is surgical. Classical removal of the tumor carries a high risk of damage of arteries and nerves. We present a case report of high localization (C1) carotid chemodectoma removal in a hybrid operating room. Tumor was successfully removed after selective embolization of chemodectoma with protection of distal flow of the internal carotid artery. This approach helped to minimize intraoperative blood loss, as well as to shorten time of intervention.

References

1.     De Franciscis S, Grande R, Butrico L, et al. Resection of Carotid Body Tumors reduces arterial blood pressure. An underestimated neuroendocrine syndrome. International Journal of Surgery. 2014; 12: 63-67.

https://doi.org/10.1016/j.ijsu.2014.05.052

2.     Serra R, Grande R, Gallelli L, et al. Carotid body paragangliomas and matrix metalloproteinases. Annals of Vascular Surgery. 2014, 28(7): 1665-1670

https://doi.org/10.1016/j.avsg.2014.03.022

3.     Luo T, Zhang C, Ning YC, et al. Surgical treatment of carotid body tumor: Case report and literature review. J. Geriatr. Cardiol. 2013; 10: 116-118.

https://doi.org/10.3969/j. issn.1671-5411.2013.01.018

4.     Sajid MS, Hamilton G, Baker DM. A multicenter review of carotid body tumor management. Eur. J. Vasc. Endovasc. Surg. 2007: 34(2): 127-130.

https://doi.org/10.1016/j.ejvs.2007.01.015

5.     Knight TTJr., Gonzalez JA, Ray JM, Rush DS. Current concepts for the surgical management of carotid body tumor. Am. J. Surg. 2006; 191: 104-110.

https://doi.org/10.1016/j.amjsurg.2005.10.010

6.     Scudder CL. Tumor of the inter carotid body. A report of one case, together with one case in the literature. Am J Med Sci. 1903; 126: 384-9.

7.     Dickinson PH, Griffin SM, Guy AG, McNeill IF. Carotid body tumor: 30 years experience. Dr J Surg. 1986; 73: 14-6.

https://doi.org/10.1002/bjs.1800730107

8.     Amato B, Serra R, Fappiano F, et al. Surgical complications of carotid body tumors surgery: a review. Int Angiol. 2015; 34(6.1): 15-22.

9.     Lim JY, Kim J, Kim SH, et al. Surgical treatment of carotid body paragangliomas: outcomes and complications according to the Shamlin classification. Clin Exp Otorhinolaryngol. 2010; 3(2): 91-5.

https://doi.org/10.3342/ceo.2010.3.2.91

10.   Amato B, Bianco T, Compagna R, et al. Surgical resection of carotid body paragangliomas: 10 years of experience. American Journal of Surgery. 2014; 207(2): 293-298.

https://doi.org/10.1016/j.amjsurg.2013.06.002

11.   Sahin MA, Jahollari A, Guler A, et al. Results of combined preoperative direct percutaneous embolization and surgical excision in treatment of carotid body tumors. Vasa. 2011; 40(6): 461-6.

https://doi.org/10.1024/0301-1526/a000149

12.   Thakkar R, Qazi U, Kim Y, et al. Technique and role of embolization using ethylene vinylalcohol copolymer before carotid body tumor resection. Clin. Pract. 2014; 4(3).

https://doi.org/10.4081/ср.2014.661

13.   Carroll W, Stenson K, Stringer S. Malignant carotid body tumor. Head Neck. 2004; 26(3): 301-306.

https://doi.org/10.1002/hed.20017

14.   Shamblin WR, Remine WH, Sheps SG, Harrison EG. Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. Am J Surg. 1971; 122(6): 732-739.

https://doi.org/10.1016/0002-9610(71)90436-3

15.   Arya S, Rao V, Juvekar S, Dcruz AK. Carotid body tumors: objective criteria to predict the Shamblin group on MR imaging. AJNR Am J Neuroradiol 2008; 29(7): 1349-54.

16.   Wu J, Liu S, Feng L, et al. Clinical analysis of 24 cases of carotid body tumor. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015: 50(1): 25-27.

https://doi.org/10.3174/ajnr.A1092

17.   Базылев В.В., Шматков М.Г., Морозов З.А. Стентирование сонных артерий как этап в лечении пациентов с билатеральным поражением каротидного бассейна и сопутствующим поражением коронарного русла. Кардиология и сердечно-сосудистая хирургия. 2012; 5(5): 39-48.

Bazilev VV, Shmatkov MG, Morozov ZA. Carotid artery stenting as a stage in treatment of patients with bilateral carotid lesions and concomitant coronary affection. Kardiologiya i serdechno-sosudistaya khirurgiya. 2012; 5(5): 39-48 [In Russ].

18.   Базылев В.В., Шматков М.Г., Морозов З.А. и др. Сравнение показателей качества жизни пациентов, перенесших каротидную эндартерэктомию и стентирование сонных артерий. Диагностическая и интервиционная радиология. 2017; 11(11): 54-58.

Bazylev VV, Shmatkov MG, Morozov ZA, et al. Comparison of Indicators of quality of life in patients undergoing carotid endarterectomy and carotid stenting. Diagnosticheskaya i Interventsionnaya radiologiya. 2017; 11(11): 54-58 [In Russ].

Abstract:

Currently, endovascular correction has become the method of choice in most cases of secondary atrial septal defects.

The obvious superiority lies in low trauma, a decrease in the incidence of early complications, atrial flutter and fibrillation, systemic thromboembolism, ischemic stroke, and all-cause mortality.

We present the initial experience of using new occluders for ASD closure.

References

1.     Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American heart association task force on practice guidelines (Writing committee to develop guidelines on the management of adults with congenital heart disease). Developed in collaboration with the American society of echocardiography, heart rhythm society, international society for adult congenital heart disease, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2008; 52: 143-263.

2.     King TD, Thompson SL, Steiner C, et al. Secundum atrial septal defect. Nonoperative closure during cardiac catheterization. JAMA. 1976; 235: 2506-2509.

3.     Alexi-Meskishvili VV, Konstantinov IE. Surgery for atrial septal defect: from the first experiments to clinical practice. Ann Thorac Surg. 2003; 76: 322-327.

4.     Nassif М, Abdelghani М, Bouma J, et al. Historical developments of atrial septal defect closure devices: what we learn from the past. Expert Review of Medical Devices. 2016; 13(6).

5.     Регистрационное удостоверение на медицинское изделие от 30 марта 2020 года № РЗН 2020/9850: «Окклюдер кардиологический «NanoMed» по НАЕФ.942511.015 ТУ.

Registration certificate for medical device, March 30, 2020 No. RZN 2020/9850: «NanoMed cardiological occluder» ac. to NAEF.942511.015 [In Russ].

6.     Базылев В.В., Шматков М.Г., Пьянзин А.И., Морозов З.А. «Отдаленные результаты применения отечественных коронарных стентов с биоинертным углеродным покрытием «Наномед». Журнал Диагностическая и интервенционная радиология. 2020; 14(1); 47-54.

Bazylev VV, Shmatkov MG, Pianzin AI, Morozov ZA. Long-term results of using domestic coronary stents with bioinert carbon coating, «Nanomed». Journal Diagnostic & interventional radiology. 2020; 14(1); 47-54 [In Russ].

https://doi.org/10.25512/DIR.2020.14.1.05

7.     Базылев В.В., Шматков М.Г., Морозов З.А. «Сравнительные результаты использования коронарных стентов с лекарственным покрытием «НаноМед» и Orsiro. Журнал Диагностическая и интервенционная радиология. 2019; 13(4); 21-26.

Bazylev VV, Shmatkov MG, Morozov ZA. Comparison of results of the use of coronary stents with drug eluting, «Nanomed» and Orsiro. Journal Diagnostic & interventional radiology. 2019; 13(4); 21-26 [In Russ].

https://doi.org/10.25512/DIR.2019.13.4.02

8.     Majunke N, Sievert H. ASD/PFO devices: what is in the pipeline? J Interv Cardiol. 2007; 20: 517-523.

9.     Aytemir K, Oto A, Ozkutlu S, et al. Early-midterm follow-up results of percutaneous closure of the interatrial septal defects with occlutech figulla devices: a single center experience. J Interv Cardiol. 2012; 25: 375-381.

10.   Haas NA, Happel CM, Soetemann DB, et al. Optimal septum alignment of the Figulla(R) Flex occluder to the atrial septum in patients with secundum atrial septal defects. EuroIntervention. 2016: 11(10):1153-60.

https://doi.org/10.4244/EIJY14M12_09

11.   Roymanee S, Promphan W, Tonklang N, et al. Comparison of the Occlutech (R) Figulla (R) septal occluder and Amplatzer (R) septal occluder for atrial septal defect device closure. Pediatr Cardiol. 2015; 36: 935-941.

12.   Sharifi M, Burks J. Efficacy of clopidogrel in the treatment of post-ASD closure migraines. Catheter Cardiovasc Interv. 2004; 63: 255.

Abstract:

Aim: was to determine the influence of blood plasma fibrinogen level on results of the left main coronary artery stenting.

Material and methods: clinical, laboratory and angiographic parameters of 819 patients after elective stenting of the unprotected left main coronary artery were used. The end-point was target lesion failure (TLF), including adverse events as repeated revascularization of the target lesion (TLR), myocardial infarction (MI) and death from cardiac causes.

Results: in 5 years follow-up period, end-point was achieved in 158 cases (19,3%). Independent predictors of TLF were: SyntaxScore > 32 (HR 1,089 95% CI 1,029-1,153, p = 0,003), creatinine level (HR 1,009 95% CI 1,004-1,013, p=0,001) and fibrinogen level (HR 1,4 95% CI 1,169-1698, p=0001). According to results of the Kaplan-Meier analysis, the cumulative probability of the TLF was higher in patients with fibrinogen values greater than 3,48 g/L (log-rank 0,001).

Conclusion: blood plasma fibrinogen level was an independent predictor of the TLF after left main coronary artery stenting. Increase in the level of blood fibrinogen for each 1 g/L led to an increase in the risk of TLF by 1,4 times per month.

References 

1.     G?n?reux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014; 63: 619.

2.     Kurtul A, Yarlioglues M, Murat SN, et al.The associationof plasmafibrinogen with the extent andcomplexity of coronary lesions in patients with acute coronary syndrome. Kardiol Pol. 2016; 74: 338-345.

3.     Jiang P, Gao Z, Zhao W, et al. Relationship between fibrinogen levels and cardiovascular events in patients receiving percutaneous coronary intervention: a large single-center study. Chinese Medical Journal. 2019; 132(8).

4.     Ang L, Behnamfar O, Palakodeti S, et al. Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. JAHA. 2017; 117.

5.     Gershlick A, Kandzar D, Banning A, et al. Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site. Results From the EXCEL Trial. JACC. 2018; 11(13).

6.     Castell JV, Gomez-Lechon MJ, David M, et al. Acutephase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990; 12: 1179-1186.

7.     Rahel BM, Visseren FLJ, Suttorp M, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003; 60: 136-140.

8.     Ou Baiqing, Yang Yulian, Chen Zhimin, et al. The Effect of Lumbrokinase on the Fibrinogen Increase Following Percutaneous Coronary Intervention. Chinese Journal of new Drugs. 2004; 13(12): 1158-60.

9.     Shi Y, Wu Y, Bian C, et al. Predictive value of plasma fibrinogen levels in patients admitted for acute coronary syndrome. Tex Heart Inst J. 2010; 37: 178-183.

10.   Corrado E, Novo S. Role of inflammation and infection in vascular disease. Acta Chir Belg. 2005; 105: 567-579.

11.   Ehtisham M, Mattheus R, Enright K, et al. Effect of Serum Fibrinogen, Total Stent Length, and Type of Acute Coronary Syndrome on 6-Month Major Adverse Cardiovascular Events and Bleeding Following Percutaneous Coronary Intervention. The American Journal of Cardiology. 2016; 117(10): 1575-1581.

12.   Otsuka M, Hayashi Y, Ueda H, et al. Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis. 2002; 164: 371-378.

13.   Kavitha S, Sridhar M, Satheesh S. Periprocedural plasma fibrinogen levels and coronary stent outcome. Indian heart journal. 2015; 67: 440-443.

Abstract

Introduction: article presents the first experience and long-term results of using domestic coronary balloon-expandable stents with a bioinert carbon coating, «Nanomed».

Aim: was to evaluate long-term results of using domestic coronary balloon-expandable stents with bioinert linear chain carbon coating (BLCCC), «Nanomed».

Materials and methods: the study included 387 patients, suffering from coronary heart disease, who underwent endovascular myocardial revascularization from 2016 to 2018, with implantation of coronary balloon-expandable stents with BLCCC by the Nanomed company, Penza. The control group included 320 patients who underwent endovascular myocardial revascularization with implantation of coronary balloon-expandable cobalt-chromium stents «MSure Cr» of the company «Multimedics», during the same period. A comparative estimation of long-term results was carried out on the basis of a study of the overall frequency of repeated myocardial revascularization; repeated interventions on the target vessel; the frequency of interventions on other coronary arteries with the progression of atherosclerosis; long-term survival rates.

Results: in the long-term period, the overall probability of absence of repeated revascularization in 47 months after PCI was 78,3 ± 2.1% and 72,1 ± 2.4% in the «Nanomed» BLCCC and «MSure Cr» groups, respectively. There was no statistically significant difference between groups (Log. Rank=0,77). However, the incidence of restenosis in the stent was statistically significantly higher in the «MSureCr» group. (p = 0,027). The overall probability of survival in 47 months after surgery was 98,2±2,4% and 98,1±2.6% in groups 1 and 2, respectively. No statistically significant difference between groups was found (Log. Rank=0,4).

Conclusions: 1. The use of a coronary balloon-expandable stent with a BLCCC, Nanomed for endovascular myocardial revascularization is an effective treatment in patients with coronary heart disease.

2. Long-term results of using bioinert carbon-coated stents, Nanomed and MSureCr stents were comparable in terms of absence of myocardial re-revascularization procedures due to relapse of the angina pectoris and survival time of up to 47 months. However, the incidence of restenosis in a stent with a bioinert carbon coating, Nanomed was statistically significantly lower.

References

1.     Allender S, Scarborough P, O’Flaherty M, Capewell S. Patterns of coronary heart disease mortality over the 20th century in England and Wales: Possible plateaus in the rate of decline. BMC Public Health 2008, 8, 148.

2.     De Scheerder I, Wang K, Wilczek K et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation. 1997; 95: 1549-1553.

3.     Morice M, Urban P, Greene S, Schuler G, Chevalier B. Why are we still using Coronary Bare-Metal Stents? JACC 2013;61;1122-3.

4.     De Mel A, Cousins BG, Seifalian AM. Surface modification of biomaterials: A quest for blood compatibility. Int. J. Biomater. 2012;  707863:1-707863:8.

5.     Kochkina K, Protopopov A. Comparative results of the use of stents with drug and carbon coatings in treatment of patients with all forms of acute coronary syndrome in the long-term follow-up. Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2014; 1:52-58 [In Russ].

6.     Carrie D, Lefevre T, Cherradi R, et al. Does Carbofilm coating affect in-stent intimal proliferation? A randomized trial comparing Rx multi-link penta and TecnicCarbostent Stents: SIROCCO Trial. J Interv Cardiol. 2007; 20(5):3818.

7.     De Mel A, Jell G, Stevens MM, Seifalian AM. Biofunctionalization of biomaterials for accelerated in situ endothelialization: A review. Biomacromolecules. 2008; 9: 2969-2979.

8.     Hofma SH, Whelan DM, van Beusekom HM, Verdouw PD, van der Giessen WJ. Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model. Eur. Heart J. 1998; 19: 601-609.

9.     Wu KK, Thiagarajan, P. Role of endothelium in thrombosis and hemostasis. Annu. Rev. Med. 1996, 47, 315-331.

10.   Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006; 193-202.

11.   Farb A, et al., Pathology of acute and chronic coronary stenting in humans. Circulation. 1999; 99(1): 44-52.

12.   Sarno G, et al., Lower risk of stent thrombosis and restenosis with unrestricted use of 'newgeneration' drug-eluting stents: a report from the nation wide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;  33(5): 606-13.

13.   Palmerini T, et al., Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;  379(9824): 1393-402.

14.   Antoniucci D, Bartorelli A, Vaenti R, et al. Clinical and angiographic outcome after coronary artery stenting with the Carbostent. Am J Cardiol. 2000; 85: 821-825.

15.   Antoniucci D, Valenti R, Migliorini A, et al. Clinical and angiographic outcomes following elective implantation of the Carbostent in patients at high risk of restenosis and target vessel failure. CathetCardiovasc Interv. 2001; 54: 420-426.

16.   Gian B Danzi, Cinzia Capuano, Marco Sesana et al. Six-Month Clinical and Angiographic Outcomes of the Technic Carbostent(TM) Coronary System: The Phantom IV Study. J Invasive Cardiol. 2004; 16(11): 641-4.

17.   Wiemer M, Butz T, Schmidt W, Schmitz KP, Horstkotte D, Langer C. Scanning electron microscopic analysis of different drug eluting stents after failed implantation: From nearly undamaged to major damaged polymers. Catheter. Cardiovasc. Interv. Off. J. Soc. Cardiac. Angiogr. Interv. 2010; 75: 905-911.

18.   Pendyala L, Jabara R, Robinson K, Chronos N. Passive and active polymer coatings for intracoronary stents: Novel devices to promote arterial healing. J. Interv. Cardiol. 2009; 22: 37-48.

19.   Kesavan S, Strange J, Johnson T et al. First-in-man evaluation of the MOMO cobalt-chromium carbon-coated stent. EuroIntervention 2013; 8:1012-1018.

20.   Jung JH, Min PK, Kin JY, Park S, Choi EY, Ko YG, Choi D, Jang Y, Shim WH and Cho SY: Does a carbon ion-implanted surface reduce the restenosis rate of coronary stents? Cardiology. 2005; 104 (2): 72-75,

21.   Kim Y, Whan Lee C, Hong M et al. Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: The Asian Pacific Multicenter Arthos Stent Study (PASS) trial. American Heart Journal. 2005; 149 (2).

22.   George Cesar Ximenes Meireles, Luciano Mauricio de Abreu, Antonio Artur da Cruz Forte et al . Randomized comparative study of diamond-like carbon coated stainless steel stent versus uncoated stent implantation in patients with coronary artery disease. Cardiol. Sro Paulo Apr. 2007; 88 (4).

23.   Ben-Dor I, Waksman R, Pichard A.et al. The Current Role of Bare-Metal Stents. Cardiac interv. 2011; 1:40-45.

24.   Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and metaanalysis. Am Heart J. 2007; 154:221-31.

25.   Bartorelli A, Trabattoni D, Montorsi P Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study. Catheter Cardiovasc Interv. 2002 Feb; 55(2):150-6.

26.   Goods C, Al-Shaibi, Liu M et al. Comparison of aspirin alone versus aspirin plus ticlopidin after coronary artery stenting. Am J Cardiol. 1996; 78:1042-1044.

27.   Leon M, Baim D,Popma J et al. A clinical trial comparing three anthitrombotic drug regimens after coronary artery stentings. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998; 339:1665-1671.

28.   Braun P et al. Prospective randomized study of the restenotic process in small coronary arteries using a Carbofilm coated stent in comparison with plain old balloon angioplasty: a multicenter study. Catheter Cardiovasc Interv. 2007 Dec 1; 70(7):920-7.

29.   Taema K, Moharram A. Long Term Clinical Follow-up of Carbon Coated Stents: Comparative Study with Bare-Metal Stents Med. J. Cairo Univ. 1-8, March: 18, 2014; 82 (2). 

Abstract

Aim: was to compare annual results of the use of stents with drug eluting - «NanoMed» and Orsiro.

Material and methods: in a randomized prospective study, an analysis of clinical and angiographic data of 1040 patients after stenting of coronary arteries with the observation period of 12 months was performed. The study and control groups randomly included 520 patients with implanted stents «NanoMed» and Orsiro.

Results: main initial clinical demographic and angiographic indicators did not statistically significantly differ. The primary endpoint (TLF - target lesion failure) was achieved in 6.5 and 5.9% in «NanoMed» and Orsiro groups, respectively (p = 0.7). Target lesion revascularization (TLR) was performed in study and control groups, respectively, in 1.7 versus 1.2% of cases (p = 0.4).

Conclusion: thus, in a comparative analysis of the use of stents «NanoMed» and Orsiro for a period of 12 months - no statistically significant difference was revealed.

References

1.     El-Hayek G, Bangalore S, Casso Dominguez A, et al. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC Cardiovasc. Interv. 2017; 10(5): 462-473.

2.     Joner M, Finn A, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006; 48: 193-202.

3.     Sarno G, Lagerqvist B, Fmbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of 'newgeneration' drug-eluting stents: a report from the nation wide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur. Heart J. 2012; 33(5): 606-613.

4.     ittelbach M, Diener T Orsiro - the first hybrid drug-eluting stent, opening up a new class of drug-eluting stents for superior patient outcomes. Interv. Cardiol. 2011; 6(2):142-144.

5.     Kandzari D, Mauri L, Koolen J, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularization (BIOFLOW V): a randomised trial. Lancet. 2017; 390: 1843-1852.

6.     Cutlip D, Windecker S, Mehran R, et al. Clinical End Points in Coronary Stent Trials. A Case for Standardized Definitions. Research Consortium. Circulation. 2007; 115(17): 2344-2351.

7.     Thygesen K, Alpert J, Jaffe A, et al. Third Universal Definition of Myocardial Infarction. ESC/ACCF/AHA/WHF Expert consensus document. Circulation. 2012; 126: 2020-2035.

8.     Silber S, Windecker S, Vranckx P, Serruys PW. Unrestricted randomiseduse of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers Trial. Lancet. 2011; 377: 1241-1247.

9.     Bazylev VV, SHmatkov MG, Morozov ZA. Comparative evaluation of endothelialization of stents with permanent and biodegradable coatings at an early stage with help of optical coherence tomography. Diagnosticheskaya i intervencionnaya radiologiya. 2017: 11(4): 11-15. [In Russ]

10.   Bazylev VV, SHmatkov MG, Morozov ZA. Comparative results of the use of coronary stents with drug coating «Nanomed» and Orsiro. Angiologiya i sosudistaya hirurgiya. 2019 ; 25(2): 57-62. [In Russ]

11.   Prohorihin AA, Bajstrukov VI, Grazhdankin IO, et al. Simple, blind, prospective, randomized, multicenter study of the efficacy and safety of the KalIpso sirolimus-eluting coronary stent and the XiencePrime everolimus-eluting coronary stent: PATRIOT study results. Patologiya krovoobrashcheniya i kardiohirurgiya. 2017; 21(3): 76-85. [In Russ]

Abstract:

Aim: was to identify risk factors of early adverse cerebral events after carotid artery stenting anc endarterectomy

Materials and methods: 908 patients who underwent isolated carotid stenting (N = 522) and carotid endarterectomy (N = 386) were included in this retrospective analysis. Patients with simultaneous cardiac surgery and patients with symptomic stenosis of CA were excluded from research. The primary end point was ipsilateral perioperative ischemic stroke, proved by neurologist and CT/MRI data. To identify predictors, multivariate regression was used, with factors that could influence endovascular and surgical methods of treatment.

Results: patients from two groups were similar in main clinical and demographic characteristics. There were no deaths and cerebral hemorrhagic complications. The stroke rate in the endovascular and surgical groups was 1.7% and 1.04% respectively (p = 0.5). The total rate of strokes and transitory ischemic attack (TIA) using two methods was 1.4%. The TIA rate was higher in the endovascular group without statistically difference (1.3% vs. 0.3%, p = 0.1). The regression analysis showed that predictor of the adverse cerebral events was the degree of carotid artery stenosis in endovascular group (OR 1.318, 95% CI: 1.131-1.535, p <0.001). There were no any predictive factors of TIA or stroke in the surgical group.

Conclusions: the independent predictor of early TIA and stroke in endovascular group, unlike endarterectomy, was the degree of carotid stenosis.

References

1.      Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. 2011 ASA/ACCF/AHA/AANN/ AANS/ACR/ ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease:executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force of Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventionalSurgery, Society for Vascular Medicine, and Society for VascularSurgery. Developed in collaboration with the American Academyof Neurology and Society of Cardiovascular Computed Tomography Catheter Cardiovasc Interv 2013; 81:76-123.

2.      Sakai N, Yamagami H, Matsubara Y et al. Prospective registry of carotid artery stenting in Japan: investigation on device and antiplatelet for carotid artery stenting. J Stroke Cerebrovasc Dis.2014; 23: 1374-1384.

3.      Jhang K, Huang J, NforIs O et al. Is Extended Duration of Dual Antiplatelet Therapy After Carotid Stenting Beneficial? Medicine 2015; 94:40.

4.      Mo D, Wang B, Ma N, et al. Comparative outcomes of carotid artery stenting for asymptomatic and symptomatic carotid artery stenosis: a single-center prospective study. J Neurointerv Surg. 2016; 8(2): 126-129.

5.      Bonati LH, Dobson J, Featherstone RL, et al. Longterm outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the Internation al Carotid Stenting Study (ICSS) randomised trial. Lancet. 2015; 385: 529-538.

6.      Stingele R, Berger J, Alfke K, et al. Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol 2008; 7: 216-222.

7.      Howard VJ, Lutsep HL, Mackey A, et al. Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Lancet Neurol 2011; 10: 530-537.

8.      Setacci C, Chisci E, Setacci F, et al. Siena carotid artery stenting score: a risk modeling study for individual patients. Stroke 2010; 41: 1259-1265.

9.      AbuRahma AF, Alhalbouni S, Abu-Halimah S, et al. Impact of chronic renal insufficiency on the early and late clinical outcomes of carotid artery stenting using serum creatinine vs glomerular filtration rate. J Am Coll Surg 2014; 218: 797- 805.

10.    Kofoed SC, Wittrup HH, Sillesen H, Nordestgaard BG. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study. Eur Heart J 2003;24:567-576.

11.    Dosa E, Rugonfalvi-Kiss S, Prohaszka Z, Szabo A, Karadi I, Selmeci L, et al. Marked decrease in the levels of two inflammatory markers, hs-C-reactive protein and fibrinogen in patients with severe carotid atherosclerosis after eversion carotid endarterectomy. Inflamm Res 2004; 53:631-635.

12.    Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19:1368-1377.

13.    Gray WA,Yadav JS, Verta P, et al. The CAPTURE registry: predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting. Catheter Cardiovasc Interv 2007; 70: 1025-1033.

14.    Theiss W, Hermanek P, Mathias K, et al. Predictors of death and stroke after carotid angioplasty and stenting: a subgroup analysis of the Pro-CAS data. Stroke 2008; 39: 2325-2330.

15.    Chaturvedi S, Matsumura JS, Gray W, et al. Carotid artery stenting in octogenarians: periprocedural stroke risk predictor analysis from the multicenter Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events (CAPTURE 2) clinical trial. Stroke 2010; 41: 757-64.

16.    Mathur A, Roubin GS, Iyer SS, et al. Predictors of stroke complicating carotid artery stenting. Circulation 1998; 97: 1239-1245.

17.    Nicolaides AN, Kakkos SK, Kyriacou E, Griffi n M, Sabetai M, Thomas DJ, et al. Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. J Vasc Surg 2010;52:1486-1496.

18.    Obeid T, Arnaoutakis DJ, Arhuidese I, et al. Poststent ballooning is associated with increased periprocedural stroke and death rate in carotid artery stenting. J Vasc Surg 2015; 62: 616-623.

19.    Aronow HD, Gray WA, Ramee SR, et al. Predictors of neurological events associated with carotid artery stenting in high-surgical-risk patients. Circ Cardiovasc Interv 2010; 3: 577-584.

 Abstract:

Aim: was to compare endothelialization of stents with permanent and biodegradable coatings at an early stage with help of optical coherence tomography (OCT).

Materials and methods: this study is a prospective, randomized trial that includes a comparative analysis of OCT data in patients after implantation of coronary stents with biodegradable (study group) and permanent coatings (control group). 98 patients were randomized 1:1 into 2 groups. After 3 months, 10 patients from each group - were randomized to conduct OCT.

Results: we analyzed OCT data of 10 studies in the biodegradable group (1,776 struts and 247 sections) and 10 studies in the permanent coating group (1562 struts and 226 sections). There were no differences in proportion of uncovered (8,9% vs. 8,5%, p=0,49) and non-exposed struts (1,6% vs. 1,3%, p=0,2). Thus, 98,4% of struts in study group and 98.7% in control group were endothelialized.

Conclusions: according to OCT data, similar results were obtained in both groups. After 3 months of observation in two groups, the overwhelming number of struts were endothelialized. At the early stage of observation, none of groups, achievement of endpoints was detected. 

References

1.     Mauri L., Kereiakes D., Yeh R. et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med. 2014; 371:2155-2166.

2.     Authors/Task Force members , Windecker S., Kolh P., et al. ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619.

3.     Kim S., Kim J.S., Shin D.H., et al. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol. 2013;111:1-5.

4.     Izumi D., Miyahara M., Sakai M., Fukuoka S. OCT- based comparison of early strut coverage between zotarolimus- and everolimus-eluting stents with second stent designs. Eurointervention. 2014;5;20.

5.     Ormiston J., Webster M., Stewart J. et al. First-inHuman Evaluation of a Bioabsorbable Polymer-Coated Sirolimus-Eluting Stent. JACC: Cardiovasc int 2013; 6(10): 1026-1034.

6.     Karjalainen P, Varho V., Nammas W. et al. Early Neointimal Coverage and Vasodilator Response Following Biodegradable Polymer Sirolimus-Eluting vs. Durable Polymer Zotarolimus-Eluting Stents in Patients With Acute Coronary Syndrome. Circulation Journal .2015;79(2): 360-367. 

Abstract:

Aim: was to evaluate the safety and efficacy of coronary stents «MedEng» and to compare them with results of the use of other coronary stents.

Materials and methods: the study included 147 patients with coronary artery disease, which in the period from January to March 2014 underwent coronary stenting. Stents «MedEng» were implanted in 61 patients (group 1). The second group (control) consisted of 86 patients who underwent implantation of stents «Driver». Average follow-up was 6,2±0,5 months. Endpoints were: the return or retention of not less than 2 angina functional class (on CCS); death by cardiac causes, myocardial infarction (MI), repeated intervention on the target vessel, restenosis> 50%, confirmed by angiography and/or the data of optical coherence tomography (OCT)

Results: success rate of stenting was 100%. Death and MI during follow-up were not observed. Restenosis was observed in 9(14,7%) patients in group «MedEng» and in 13 (15,1%) patients from «Driver» group (p = 0,9). The average degree of coronary restenosis was 76,1±8,4% and 76,2±6,4% in the first and second groups, respectively (p=0.9). According to results of logistic regression, stents «MedEng» was not a predictor of restenosis (OR=1,998; 95% CI (0,158-312,551); p = 0,314).

Conclusions: the use of stents «MedEng» is safe and effective in myocardial revascularization. Results of implantation of stents «MedEng» do not different from results of the use of stents «Driver».  

References 

1.    Hoffmann R., Mintz G. Coronary in-stent restenosis - predictors, treatment and prevention. European Heart Journal 2000; 21: 1739-1749.

2.    Ben-Dor I., Waksman R., Pichard A.et al. The Current Role of Bare-Metal Stents. Cardiac interv. 2011; 1: 57-62.

3.    Kastrati A., Sch^mig A., Elezi S., Dirschinger J et al. Prognostic Value of the Modified American College of Cardiology/American Heart Association Stenosis Morphology Classification for Long-Term Angiographic and Clinical Outcome After Coronary Stent Placement. Circulation. 1999; 100: 1285-1290.

4.    Lagerqvist B., James S., Stenestrand U., Lindbck J., Nilsson T., Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 2007; 356: 1009-1019

5.    Sketch M., Ball M., Rutherford B., Popma J.J., Russell C., Kereiakes D.J. Driver Investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am. J. Cardiol. 2005;95:8-12.

6.    Farb A., et al., Pathology of acute and chronic coronary stenting in humans. Circulation. 1999; 99(1): p. 44-52.

7.    Sarno G., et al. Lower risk of stent thrombosis and restenosis with unrestricted use of newgeneration drug-eluting stents: a report from the nation wide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur. Heart J. 2012; 33(5): p. 606-13.

8.    Camenzind E., Steg P., Wijns W. Stent thrombosis late after implantation of First-generation drug-eluting stents: a cause for concern. Circulation. 2007; 115: 1440-155.

9.    Lagerqvist B., James S., Stenestrand U., Lindbck J., Nilsson T., Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N.Engl. J. Med. 2007; 356: 1009-1019.

10.  Bavry A., Kumbhani D., Helton T., et al. Late thrombosis of drug-eluting stents: a metaanalysis of randomized clinical trials. Am. J. Med. 2006;119:1056-1061.

11.  Morice M., Urban P., Greene S., Schuler G., Chevalier B. Why are we still using Coronary Bare-Metal Stents? JACC. 2013;61;1122-3.

12.  Steinberg D., Mishra S., Javaid A., et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (>3.5 mm) coronary arteries. Am. J. Cardiol. 2007;99:599-602.

13.  Kim T., Nam C., Hur S., et al. Two-year clinical outcomes after large coronary stent (4.0 mm) placement: comparison of bare-metal stent versus drug-eluting stent. Clin. Cardiol. 2010;33:620-625.

14.  Bocksch W., Pomar F., Dziarmaga M., Tresukosol D et al. Clinical safety and efficacy of a novel thin-strut cobalt-chromium coronary stent system: results of the real world Coroflex Blue Registry. Catheter Cardiovasc. Interv. 2010 Jan 1;75(1):78-85.

15.  Cassese S., Byrne R., Tada T. et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart.2014 Jan;100(2):153-9.

16.  Serruys P., Morice M., Kappetein A., et al. SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl. J. Med. 2009;360:961-972.

Abstract:

We present report of successful full revascularization of heart during additional adjuvant extracorporeal revascularization (EcR) in case of difficult anatomy of anatomically difficult, multivessel lesions of coronary arteries and reduced ejection fraction (EF) of left ventricular (LV).  

Abstract:

A case report of right ventricular outlet (RVO) stenting as palliative treatment of pulmonary artery atresia (PAA) in combination with interventricular septum defect (ISD), in situation when radical surgical intervention has high operative risk due to condition severity and low weight RVO stenting in newborn and children with low weight is made seldom and noted as a case reports. Peculiarity of this case is that intervention was made in patient with extremely low weight and age (age - 6 month, weight - 3 kg) after performed early central aorto-venous bypass and further palliative reconstruction of right ventricular outflow.

References

1.     Chang A.C., Hanley F.L., Lock J.E., et. al. Management and outcome of low birth weight neonates with congenital heart disease. J. Pediatr. 1994; 124: 461-6.

2.     Reddy V.M., Elhinney D.B., Sagrado T., et.al. Results of 102 cases of complete repair of congenital heart defects in patients weighing 700 to 2500 grams. Thorac. Cardiovasc. Surg. 1999; 117: 324-31.

3.     Wernovsky G., RubensteinS.D., Spray T.L. Cardiac surgery in the low-birth weight neonate: new approaches. Clin. Perinatol. 2001; 28:249-4.

4.     Laudito А., Varsha M., Bandisode J., Lucas F. et al. Right Ventricular Outflow Tract Stent as a Bridge to Surgery in a Premature Infant with Tetralogy of Fallot. Ann. Thorac. Surg. 2006; 81:744-746.

5.     Kirklin J. V., Barrat-Boyes. Cardiac surgery J V. New York: Churhill Livingstoun 2003.

6.     Sahu Raj., Syamasundar Rao., Transcatheter Stent Therapy in Children: An Update. Pediat. Therapeut. 2012, S5.

7.     Meadows J., Catheter-Based Interventions for Congenital Heart Disease Meadows Jeff. J. Clin. Exp. Cardiolog. 2012, S: 8.

8.     Gibbs J.L., Uzun O., BlackburnM.E., et. al. Right ventricular outflow stent implantation: an alternative to palliative surgical relief of infundibular pulmonary stenosis. Heart. 1997; 77:176-9.

9.     Sugiyama H., Williams W., Benson L.N. Implantation of endovascular stents for the obstructive right ventricular outflow tract Heart. 2005; 91:10581063.doi:10.1136/ hrt.2004.034819.

10.   Alwi M., Alwi M., Choo K.K., Latiff H.A., et. al. Initial results and medium-term follow-up of stent implantation in patent ductus arteriosus in ductdependent pulmonary circulation. J. Am. Coll. Cardiology 2004; 44(2):438-45. 

11.   Gladman G., Mc Crindle B.W., Williams W.G., et. al. The modified blalock-taussig shunt: clinical impact and morbidity in Fallot’s tetralogy in the currentera. J. Thorac. Cardiovasc. Surg. 1997; 114:25-30.

Abstract:

The article presents a literature review of the use of optical coherence tomography in interventional cardiology. The method of optical coherence tomography is described in details, as well as its comparison with other methods of intravascular imaging. Direct results of the use of optical coherence tomography in clinical practice in the performance of percutaneous coronary intervention have been analyzed. Article describes possibilities of assessment of long-term results after interventional procedures using optical coherence tomography in patients with coronary heart disease. Article notes possibilities of using optical coherence tomography to assess the effectiveness of treatment of patients with atherosclerotic coronary pathology using biodegradable stents.

References:

1.     Hiram G. Bezerra., Marco A. Costa., Guagliuni G. et al. Intracoronary Optical Coherence Tomography: A Comprehencive Review: Clinical and Research Applications. J.Am.Col. Cardiol. Intv. 2009; 42:1035-1046.

2.     Rollings A.M.,Ung-arunyawee R., Chak A., Wong R.C.K., Kobayashi K., SWivak M.V., Izatt J.A. Real time in vivo imaging of human gastrointestinal ultrastructure by use of endoscopic optical coherence tomography with a novel efficient interferometer design. Opr.left. 1999;24(19): 1358-1360.

3.     Adam M., Nguyenet F. T., Daniel L. M. et.al. Optical coherence tomography: a review of clinical development from bench to bedside. Journal of Biomedical Optics. 2007; 12(5): 1-13.

4.     Stephen T. Sum, , Sean P. Madden, Michael J. Hendricks, BS, Steven J. Chartier, and James E. Muller, Near-infrared spectroscopy for the detection of lipid core coronary plaques. [Spektroskopija V Blizhne-Infrakrasnoj Oblasti V Vyjavlenii Nestabil'nyh Ateroskleroticheskih Bljashek V Koronarnyh Arterijah)]. Diagnosticheskaja i intervencionnaja radiologija. 2012; 6(2): 39-51 [In Russ].

5.     Barlis P. A., Gonzalo N., SerruysP.et al.Multi-Center Evaluation of the Safety of Intra-Coronary Optical Coherence Tomography. Eurointervention. 2009; 5: 90-95.

6.     Prati F., Imola F., Mallus M. et al. Safety and feasibility of frequency domain optical coherence tomography to guide decision making in percutaneous coronary intervention. EuroIntervention.2010; 6:575-58.1

7.     Serruys P.W., Simon D. I., Costa M. et al. Clinical Research Compendium. A Summary of Cardiovascular Optical Coherence Tomography Literature. 2009; 3: 1-22.

8.     Prati F., Regar E., Gary Mintz S. et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. European Heart Journal. 2010; 31: 401-415.

9.     Kume T., Akasaka T., Kawamoto Т. е^ al. Measurement of the thickness of the fibrous cap by optical coherence tomography. Am Heart J2006; 152(4):755-4.

10.   Prati F., Cera M., Ramazzotti V. et al. Safety and feasibility- of a new non-occlusive technique for facilitated intracoronary optical coherence tomography (OCT) acquisition in various clinical and anatomical scenarios. Eurointerv. 2007;3:365-370.

11.   Gonzalo N., Patrick W., Serruys P.W., Peter Barlis., et al. Multi-modality intra-coronary plaque characterization: A pilot study. International Journal of Cardiology.2008; 138(1):32-9.

12.   Gonzalo N., Serruys P. W., Barlis P. et al. Multi-modality intra-coronary plaque characterization: A pilot study. 2008; Optical Coherence Tomography for the Assessment of Coronary Atherosclerosis and Vessel Response after Stent Implantation. 2010; 4.3:141-153.

13.   Chia S., Raffel O.C., Takano M. et al. Association of statin therapy with reduced coronary plaque rupture: An optical coherence tomography study. Coron Artery Dis. 2008; 19(4):237-42.

14.   Barlis P., Serruys P.W., Gonzalo N. et al. Assessment of culprit and remote coronary narrowings using optical coherence tomography with long-term outcomes. Am J Cardiol 2008; 15: 102(4):391-5.

15.   Jang I .K., Tearney G.J., MackNeill D. et al. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation. 2005; 111(12):1551-1555.

16.   MacNeill B., Briain D.,. Bouma B.E. et al.Focal and multifocal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J. Am. Coll. Cardiol. 2004; 44:972-9.

17.   Takarada S., Imanishi T., Kubo T. et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: Assessment by optical coherencetomography study. Atherosclerosis. 2009; 202(2):4917.

18.   Kubo T., Imanishi T., Takarada S. et al. Assessment of culprit lesion morphology in acute myocardial infarction: Ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J. Am. Coll Cardiol.2001] 50(10):933-9.

19.   Larry J., Diaz-Sandov., Diaz-Sandoval. et al. Optical coherence tomography as a tool for percutaneous coronary interventions. Catheter Cardiovasc. Interv. 2005; 65(4):492-6.

20.   Gutierrez H., Arnold R., Gimeno F. et al. Optical coherence tomography: Initial experience in patients undergoing percutaneous coronary intervention. Rev. Esp. Cardiol. 2008; 61(9): 976-9.

21.   Tanigawa J., Barlis P., Kaplan S. et al. Stent strut apposition in complex lesions Using optical coherence tomography. Am. J. Cardiеl. 2006; 98(1) :97 M.

22.   Gonzalo N., Barlis P., Serruys P.W. et al. Incomplete Stent Apposition And Delayed Tissue Coverage Are More Frequent In Drug Eluting Stents Implanted During Primary Percutaneous Coronary Intervention For ST Elevation Myocardial Infarction Than In Drug Eluting Stents Implanted For Stable/Unstable Angina. Insights from Optical Coherence Tomography. Cardiovasc Interv. 2009; 2(5): 445-52.

23.   Gonzalo N., Serruys P.W. Optical coherence tomography (OCT) in secondary revascularisation: stent and graft assessment. Euro.Intervention. 2009; 5: D93-D100.

24.   Tanigawa J., Barlis P., Dimopoulos K., Di Mario. Optical coherence tomography to assess malapposition in overlapping drug-eluting stents. EuroInterv. 2008; 3: 580-583.

25.   Gonzalo N., Garcia-Garcia H.M., Serruys P.W. et al. Reproducibility of quantitative per strut stent analysis with OCT. EuroIntervention. 2009; 5(2): 224-32.

26.   Gonzalo N., Serruys P.W., Okamura T. et al. Optical Coherence Tomography Assessment Of The Acute E?ects Of Stent Implantation On The Vessel Wall. A Systematic Quantitative Approach. E.Heart. 2009; 95(23): 1913-1919.

27.   Gonzalo N., Serruys P.W., Okamura T. et al. Optical Coherence Tomography Patterns of Stent Restenosis. Am. Heart J. 2009; 158(2): 284-93.

28.   Gonzalo N., Serruys P.W., Okamura T. et al. Relation between plaque type and dissections at the edges after stent implantation: an optical coherence tomography study. Optical Coherence Tomography for the Assessment of Coronary Atherosclerosis and Vessel Response after Stent Implantation. 2010; 6.5:249-261.

29.   Xie Y., Takano M., Murakami D. et al. Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation. Am. J. Cardiol. 2008;102:27-31.

30.   Chen B.X., Ma F.Y., Luo W. et al. Neointimal coverage of bare-metal and sirolimus-eluting stents evaluated with optical coherence tomography. Heart. 2008; 94:566-70.

31.   Matsumoto D., Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur. Heart J. 2007; 28:96 1-7.

32.   Yao Z.H., Matsubara T., Inada T, et al. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: evaluation by optical coherence tomography. Chin. Med. J. 2008;121:503-7.

33.   Takano M., Yamamoto M., Inami S. et al. Long-term follow-up evaluation after sirolimus-eluting stent implantation by optical coherence tomography: douncovered struts persist. J. Am. Cardiol. 2008; 51(9):968-9.

34.   Finn A.V., Joner M., Nakazawa G. et al. Pathological correlates of late drug-elutingstent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115(18):2435-41.

35.   Stone G., Moses J.W., Ellis S.G. et al. Safety and ef?cacy of sirolimus- and paclitaxel-eluting coronary stents. J. Med. 2007; 356(10):998-10.

36.   Kubo T., Kitabata H., Kuroi A .et al. Comparison of vascular response after sirolimus eluting stent implantation between patients with unstable and stable angina pectoris. A serial optical coherence tomography study. J. Am. Coll. Cardiol. 2008;1.

37.   Guagliumi G., Sirbi V., Costa M.A. A Long -term Strut Coverage of Paclitaxel eluting Stents Compared with Bare-Metal Stents implanted During Primary PCI in Acute Myocardial infarction A PROSPECTIVE, Randomised, Controled Study Perfomed with OCT. Horizons- OCT. Circulation. 2008;118:231.

38.   Barlis P., Regar E., Serruys PW. et al. An Optical Coherence Tomography Study of a Biodegradable versus Durable Polymer-Coated Limus-Eluting Stent: A LEADERS Trial Sub-Study. Eur. Heart J. 2010; 31:165-76.

39.   Serruys PW., Ormiston J.A., Onuma Y. et al. Bioabsorbable everolimus-eluting system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009; 373(9667): 897-910. 

Abstract:

This case report is about endovascular treatment of pulmonary arteriovenous malformations accompanied by severe arterial hypoxemia in the newborn. The peculiarity of this case is the extreme rarity of manifestation and successful treatment of the pathology in infancy The second feature was the use of vascular occlude devices. Currently due to the sporadic clinical observations in newborn, we consider to appropriate description of this case, focusing on the technical aspects of the intervention. 

References

1.     Khurshid I., Downie G. Pulmonary arteriovenous malformation. Postgrad Med J 2002; 78:191-7.

2.     Andrade C., Ferreira H., Fischer G. Congenital lung malformations. Bras. Pneumol. 2011; 37: 259-271.

3.     Churton T., Multiple aneurysms of pulmonary artery. BMJ. 1897; 1: 1223.

4.     Mitchell R., Austin E. Pulmonary arteriovenous malformation in the neonate. J. Pediatr. Surg. 1993; 28: 1536-1538.

5.     Porstmann W. Therapeutic embolization of arteriovenous pulmonary fistula by catheter technique. Current concepts in pediatric radiology. Springer. 1977; 23-31.

6.     Pollak J.S., Saluja S., Thabet A. et al. Clinical and Anatomic Outcomes after Embolotherapy of Pulmonary Arteriovenous Malformations. J. Vasc. Interv. Radiol. 2006; 17: 35-45.

7.     Cirstoveanu C., Balomir A., Bizubac M., Costinean S. Pulmonary arteriovenous malformation - a rare cause of hypoxemia. Practic. Med. 2012; 7: 28.

8.     Koppen S., Korver C., Dalinghaus M., Westermann C. Neonatal pulmonary arteriovenous malformation in hereditary haemorrhagic telangiectasia. Arch. Dis. Child. Fetal Neonatal Ed. 2002; 87: 226-227.

9.     Guidone P., Burrows P., Blickman J. Pediatric case of the day. Congenital pulmonary arteriovenous malformation. Am. J. Roentgenol. 1999; 173: 818-819.

10.   Trivedi K., Sreeram N. Neonatal pulmonary arteriovenous malformation. Arch. Dis. Child. 1996; 74: 80.

11.   Ravasse P., Maragnes P., Petit T., et al. Total pneumonectomy as a salvage procedure for pulmonary arteriovenous malformation in a newborn: report of one case. J. Pediatr. Surg. 2003; 38: 254-255.

12.   Trerotola S., Pyyeritz R . PAVM Embolization: An Update. AJR. 2010; 195: 837-845

13.   Swanson K., Prakash U., Stanson A. Pulmonary arteriovenous fistulas: Mayo Clinic experience. Mayo Clinic Proc. 1999; 74: 671-680.

14.   Shapiro J., Paul C. Stillwell - Diffused Pulmonary arteriovenous malformation (Angiodysplasia) with unusual histologic features: Case report and review of the literature. Pediatric Pulmonology 1995; 21: 255-261.

15.   Белозеров Ю.М., Детская кардиология. М.: Медпрессинформ. 2004;167-180. Belozerov Ju. M., Detskaja kardiologija [Pediatrics cardiology]. M.: Med-pressinform. 2004;167-180 [In Russ]. 

Abstract:

Revascularization strategy definition in acute coronary syndrome in patients with multivessel coronary artery disease is a significant problem of modern interventional cardiology.

Aim: was to evaluate effectiveness of special PC programs «Sapphire 2015 - Right dominance» and «Sapphire 2015 - Left dominance» designed to the revascularization strategy definition ir acute coronary syndrome patients.

Materials and methods: revascularization strategy of 50 acute coronary syndrome patients was analyzed. In all cases the revascularization strategy was defined by the group of intervention cardiologists with the help of independent experts and special PC programs «Sapphire 2015 - Right dominance» and «Sapphire 2015 - Left dominance». Experts-, physicians-, and soft- based revascularization strategies were compared among themselves

Results: complete coincidence between expert-based and soft-based revascularization strategies was registered in 66% patients and the incomplete coincidence - in 32% patients. Complete mismatch between expert-based and soft-based revascularization strategies was registered in 2% patients. The complete coincidence between physicians-based and soft-based revascularization strategies was registered in 42% patients and the incomplete coincidence - ir 52% patients. Complete mismatch between physicians-based and soft-based revascularization strategies was registered in 6% patients.

Conclusion: as well as experts, special PC programs «Sapphire 2015 - Right dominance» and «Sapphire 2015 - Left dominance» provide success in the revascularization strategy definition 1г acute coronary syndrome patients with multivessel coronary artery disease.

References

1.     ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/ SAIP/ SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Circulation. 2011; 124:54-130.

2.     Cohen D, Stolker J, Wang К, et al. Health-Related Quality of Life After Carotid Stenting Versus Carotid Endarterectomy. Results From CREST (Carotid Revascularization Endarterectomy Versus Stenting Trial). JACC Vol. 2011;15:58.

3.     Amirdjanova V.N., Goryachev D.V., Korshunov N.I., Rebrov A.P., Sorotskaya V.N. Populyatsionnie pokazateli kachestva zhizni po oprosniku SF-36 (rezultati mnogotsentrovogo issledovaniya kachestva zhizni) Mirazh. [Population' indicators of quality of life questionnaire SF-36 (results of a multicenter study of quality of life «MIRAGE»).]. Rheumatology Science and Practice. 2008;46(1):36-48. [In Russ].

4.     Stolker JM, Mahoney EM, Safley DM, et al. Health-related quality of life following carotid stenting versus endarterectomy: results from the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial. J Am Coll Cardiol Intv. 2010;3: 515-23.

5.     PQcTte E, Slisers M, Miglane E et al. Health-Related Quality of Life Among Patients with Severe Carotid Artery Stenosis. The Journal of Latvian Academy of Sciences. 2015; 5:237-242.

6.     Kazmierski P, Kasielska A, Bogusiak K, Lysakowski M, Stela О gowski M. Influence of internal carotid endarterectomy on patients’ life quality. Pol Przegl Chir. 2012;84:17-22.

7.     Shan L. Saxena A .Quality of Life and Functional Status After Carotid Revascularisation: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg. 2015;49: 634-645.

8.     Stolker JM, Mahoney EM, Safley DM, et al. Health-related quality of life following carotid stenting versus endarterectomy: results from the SAPPHIRE (Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy) trial. J Am Coll Cardiol Intv. 2010;3: 515-523.

9.     CaRESS Steering Committee. Carotid Revascularization Using Endarterectomy or Stenting Systems (CaRESS) phase I clinical trial: 1-year results. J Vasc Surg. 2005;42:213-219.